Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
- 作者: Soria J.1, Felip E.2, Cobo M.3, Lu S.4, Syrigos K.5, Lee K.6, Göker E.7, Georgoulias V.8, Li W.9, Isla D.10, Guclu S.11, Morabito A.12, Min Y.13, Ardizzoni A.14, Gadgeel S.15, Wang B.16, Chand V.16, Goss G.17
-
隶属关系:
- Gustave Roussy Cancer Campus and University Paris-Sud
- Medical Oncology Department, Vall d’ Hebron University Hospital, Vall d’ Hebron Institute of Oncology, Barcelona, Spain
- Hospital Carlos Haya, Malaga, Spain
- Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
- Athens School of Medicine, Athens, Greece
- Chungbuk National University College of Medicine, Cheongju, South Korea
- Ege University Faculty of Medicine, Izmir, Turkey
- Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Crete, Greece
- First Hospital Affiliated to Jilin University, Jilin, China
- Hospital Lozano Blesa, Zaragoza, Spain
- Izmir Chest Diseases Research Hospital, Izmir, Turkey
- Istituto Nazionale Tumori “Fondazione G Pascale”-IRCCS, Naples, Italy
- Department of Medicine, Ulsan University Hospital, Ulsan, South Korea
- University Hospital, Bologna, Italy
- Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA
- Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
- Division of Medical Oncology, University of Ottawa, Ottawa, ON, Canada
- 期: 卷 17, 编号 3 (2015)
- 页面: 42-52
- 栏目: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/27024
- ID: 27024
如何引用文章
全文:
详细
作者简介
Jean-Charles Soria
Gustave Roussy Cancer Campus and University Paris-Sud
Email: Jean-Charles.Soria@gustaveroussy.fr
Enriqueta Felip
Medical Oncology Department, Vall d’ Hebron University Hospital, Vall d’ Hebron Institute of Oncology, Barcelona, Spain
Manuel Cobo
Hospital Carlos Haya, Malaga, Spain
Shun Lu
Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
Konstantinos Syrigos
Athens School of Medicine, Athens, Greece
Ki Lee
Chungbuk National University College of Medicine, Cheongju, South Korea
Erdem Göker
Ege University Faculty of Medicine, Izmir, Turkey
Vassilis Georgoulias
Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Crete, Greece
Wei Li
First Hospital Affiliated to Jilin University, Jilin, China
Dolores Isla
Hospital Lozano Blesa, Zaragoza, Spain
Salih Guclu
Izmir Chest Diseases Research Hospital, Izmir, Turkey
Alessandro Morabito
Istituto Nazionale Tumori “Fondazione G Pascale”-IRCCS, Naples, Italy
Young Min
Department of Medicine, Ulsan University Hospital, Ulsan, South Korea
Andrea Ardizzoni
University Hospital, Bologna, Italy
Shirish Gadgeel
Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA
Bushi Wang
Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
Vikram Chand
Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
Glenwood Goss
Division of Medical Oncology, University of Ottawa, Ottawa, ON, Canada
参考
- Travis W.D. Pathology of lung cancer. Clin Chest Med 2011; 32: 669-92.
- Reck M, Popat S, Reinmuth N et al. Metastatic non - small - cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow - up. Ann Oncol 2014; 25 (Suppl. 3): iii27-iii39.
- Drilon A, Rekhtman N, Ladanyi M, Paik P. Squamous - cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol 2012; 13: e418-26.
- Scagliotti G.V, Novello S, Rapetti S, Papotti M. Current state - of - theart therapy for advanced squamous cell lung cancer. Am Soc Clin Oncol Educ Book 2013; 354-8.
- Scagliotti G, Brodowicz T, Shepherd F.A et al. Treatment - byhistology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non - small cell lung cancer. J Thorac Oncol 2011; 6: 64-70.
- Garon E.B, Ciuleanu T.E, Arrieta O et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second - line treatment of stage IV non - smallcell lung cancer after disease progression on platinum - based therapy (REVEL): a multicentre, double - blind, randomised phase 3 trial. Lancet. 2014; 384: 665-73.
- Rizvi N.A, Mazieres J, Planchard D et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non - small - cell lung cancer (CheckMate 063): a phase 2, single - arm trial. Lancet Oncol 2015; 16: 257-65
- Brahmer J, Reckamp K.L, Baas P et al. Nivolumab versus docetaxel in advanced squamous - cell non - small - cell lung cancer. N Engl J Med 2015; published online May 31. DOI: 10.1056/ NEJMoa1504627
- Hirsch F.R, Varella-Garcia M, Bunn P.A Jr et al. Epidermal growth factor receptor in non - small - cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21: 3798-807.
- Lopez-Malpartida A.V, Ludena M.D, Varela G, Garcia PJ. Differential ErbB receptor expression and intracellular signaling activity in lung adenocarcinomas and squamous cell carcinomas. Lung Cancer 2009; 65: 25-33.
- Tsao M.S, Sakurada A, Cutz J.C et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-44.
- Dearden S, Stevens J, Wu Y.L, Blowers D. Mutation incidence and coincidence in non small - cell lung cancer: meta - analyses by ethnicity and histology (mutMap). Ann Oncol 2013; 24: 2371-6.
- Clark G.M, Zborowski D.M, Santabarbara P et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non - small - cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 2006; 7: 389-94.
- Wojtowicz-Praga S, Leon L. Comparative efficacy and safety of erlotinib in non - small cell lung cancer (NSCLC) of squamous cell and adenocarcinoma histology in the phase III NCIC CTG BR.21 and saturn (BO18192) trials. Ann Oncol 2012; 23 (Suppl. 9): ix419. abstr 1277P.
- Pirker R, Pereira J.R, von Pawel J et al. EGFR expression as a predictor of survival for first - line chemotherapy plus cetuximab in patients with advanced non - small - cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012; 13: 33-42.
- Thatcher N, Hirsch F.R, Luft A.V et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first - line therapy in patients with stage IV squamous non - small - cell lung cancer (SQUIRE): an openlabel, randomised, controlled phase 3 trial. Lancet Oncol 2015; 16: 763-74.
- Heinmoller P, Gross C, Beyser K et al. HER2 status in non - small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin. Clin Cancer Res 2003; 9: 5238-43.
- Hirsch F.R, Franklin W.A, Veve R et al. HER2/neu expression in malignant lung tumors. Semin Oncol 2002; 29 (Suppl. 4): 51-8.
- Ugocsai K, Mandoky L, Tiszlavicz L, Molnar J. Investigation of HER2 overexpression in non - small cell lung cancer. Anticancer Res 2005; 25: 3061-6.
- Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519-25.
- Dhanasekaran S.M, Alejandro B.O, Chen G et al. Transcriptome meta - analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. Nat Commun 2014; 5: 5893.
- Solca F, Dahl G, Zoephel A et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012; 343: 342-50.
- Sequist L.V, Yang J.C, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327-34.
- Wu Y.L, Zhou C, Hu C.P et al. Afatinib versus cisplatin plus gemcitabine for first - line treatment of Asian patients with advanced non - small - cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open - label, randomized phase 3 trial. Lancet Oncol 2014; 15: 213-22.
- Yang J.C, Wu Y.L, Schuler M et al. Afatinib versus cisplatin - based chemotherapy for EGFR mutation - positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015; 16: 141-51.
- Miller V.A, Hirsh V, Cadranel J et al. Afatinib versus placebo for patients with advanced, metastatic non - small - cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012; 13: 528-38.
- Machiels J, Haddad R, Fayette J et al. Afatinib versus methotrexate as second - line treatment in patients with recurrent or metastatic squamouscell carcinoma of the head and neck progressing on or after platinum - based therapy (LUX-Head & Neck 1): an open - label, randomised phase 3 trial. Lancet Oncol 2015; 16: 583-94.
- Kim J.H, Grossi F, De Marinis F et al. Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/gefitinib (E/G) and chemotherapy: interim subset analysis from a phase III trial. Proc Am Soc Clin Oncol 2012; 30 (Suppl. 15): abstr 7558.
- Hamilton M, Wolf J.L, Rusk J et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006; 12: 2166-71.
- Smit E.F, Gervais R, Zhou C et al. Efficacy and safety results from CurrentS, a double - blind, randomized, phase III study of secondline erlotinib (150 mg versus 300 mg) in current smokers with advanced non - small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2014; 32 (Suppl. 5): abstr 8046.
- Li N, Yang L, Ou W et al. Meta - analysis of EGFR tyrosine kinase inhibitors compared with chemotherapy as second - line treatment in pretreated advanced non - small cell lung cancer. PLoS One 2014; 9: e102777.
- Shepherd F.A, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non - small - cell lung cancer previously treated with platinum - based chemotherapy. J Clin Oncol 2000; 18: 2095-103.
- Garassino M.C, Martelli O, Broggini M et al. Erlotinib versus docetaxel as second - line treatment of patients with advanced non - small - cell lung cancer and wild - type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 2013; 14: 981-8.
- Yi E.S, Harclerode D, Gondo M et al. High c - erbB-3 protein expression is associated with shorter survival in advanced non - small cell lung carcinomas. Mod Pathol 1997; 10: 142-48.
- Nelson V, Ziehr J, Agulnik M, Johnson M. Afatinib: emerging next - eneration tyrosine kinase inhibitor for NSCLC. Onco Targets Ther 2013; 6: 135-43.
- Garon E.B, Balmanoukian A, Hamid O et al. Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non - small cell lung cancer (NSCLC). J Thorac Oncol 2013; 8 (Suppl. 2): abstr MO18.02
- Katakami N, Atagi S, Goto K et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non - small - cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 2013; 31: 3335-41.